Filed October 22, 2025

On behalf of **Dr. Falk Pharma GmbH**
By: Nathanael Luman (Reg. No. 63,160)
Eric S. Furman (Reg. No. 45,664)
Phillip J. Minnick (Reg. No. 81,223)
KNOBBE, MARTENS, OLSON & BEAR, LLP
3579 Valley Centre Drive, Suite 300
San Diego, CA 92130
Ph: 949-760-0404
Email: BoxDRFPGL.001LP@knobbe.com

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

DR. FALK PHARMA GMBH,

Petitioner

v.

ELLODI PHARMACEUTICALS, L.P.,
Patent Owner

Case No. IPR2024-01197
Patent No. 8,771,729

PETITIONER'S UPDATED EXHIBIT LIST

Pursuant to 37 C.F.R. § 42.63(e), Petitioner Dr. Falk Pharma GmbH ("Dr. Falk") provides an updated list of its exhibits in this proceeding.

Exhibit No.	Description
1001	U.S. Patent No. 8,771,729 to Perrett et al.
1002	U.S. Publication No. 20070111978 to Dohil et al.
1003	EP2482822B1 that was revoked by the European Patent Office
1004	The Opposition Division of the European Patent Office decision revoking EP2484822B1 with auxiliary requested claims
1005	"Guidance for Industry: Orally Disintegrating Tablets," U.S. Food & Drug Administration, Center for Drug Evaluation and Research (CDER), 2008.
1006	Notice of Publication of FDA Guidance for Industry on Orally Disintegrating Tablets, Federal Register, Vol. 73, No. 242 at 76366, December 16, 2008.
1007	"DRAFT Guidance for Industry: Orally Disintegrating Tablets," U.S. Food & Drug Administration, Center for Drug Evaluation and Research (CDER), 2007.
1008	International Publication No. WO2000044351 to Grother et al.
1009	Svoboda et al., "Oral formulations of budesonide: a novel treatment for inflammatory bowel disease," Drugs of Today, 44:857-863 (2008) at 857.
1010	Tan et al., "Eosinophilic gastroenteritis treated with non-enteric-coated budesonide tablets," European Journal of Gastroenterology & Hepatology, 13:425-427 (2001)
1011	Kolkman et al., "Evaluation of oral budesonide in the treatment of active distal ulcerative colitis," Drugs of Today, 40:589-601 (2004)

Exhibit No.	Description
1012	Siewert et al., "Eosinophilic gastroenteritis with severe protein-losing enteropathy: Successful treatment with budesonide," Digestive and Liver Disease, 38:55-59 (2006)
1013	Elsing et al., "Budesonide for the treatment of obstructive eosinophilic jejunitis," Z. Gastroenterology, 45:187-189 (2007).
1014	Aceves et al., "Topical viscous budesonide suspension for treatment of eosinophilic esophagitis," Journal of Allergy and Clinical Immunology 116:705-706 (2005)
1015	Aceves et al., "Oral Viscous Budesonide: A potential new therapy for eosinophilic esophagitis in children," American Journal of Gastroenterology, 102:1-9 (2007)
1016	The United States Pharmacopeia, USP 32, 2009 at pages 262-263 "<701> Disintegration"
1017	Danckwerts, "Intraoral Drug Delivery: A Comparative Review," American Journal of Drug Delivery, 1:171-186 (2003).
1018	Fu et al., "Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies," Critical Reviews in Therapeutic Drug Carrier Systems, 21:433-475 (2004)
1019	Shukla et al., "Mouth Dissolving Tablets I: An overview of formulation technology," Scientia Pharmaceutica, 77:309-326 (2009) (March 6, 2009)
1020	U.S. Publication No. 20050232988 to Venkatesh et al.
1021-1024	RESERVED
1025	Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 11th edition, eds. Brunton, Lazo, Parker, 2005
1026	Budenofalk® Brochure (2005)
1027	Budenofalk® Advertisement (2007)

Exhibit No.	Description
1028	Dr. Falk Pharma Brochure (2008)
1029	*Curriculum Vitae* of Alan F. Parr, Pharm.D., Ph.D.
1030	Declaration of Alan F. Parr, Pharm.D., Ph.D.
1031	Prosecution history excerpts from U.S. Application No. 12/896,005, which issued as U.S. 8,771,729
1032	Prosecution history excerpts from U.S. Application No. 15/816,154, which issued as U.S. 10,632,069
1033	Teitlebaum et al., Eosinophilic esophagitis in children: Immunopathological analysis and response to fluticasone propionate," Gastroenterology 122:1216-1225 (2002)
1034	Noel et al., "Clinical and immunopathologic effects of swallowed fluticasone for eosinophilic esophagitis," Clinical Gastroenterology and Hepatology 2:568-575 (2004)
1035	U.S. Patent No. 7,122,198 to Singh et al.
1036	U.S. Patent No. 7,229,641 Cherukuri et al.
1037	RESERVED
1038	Ellodi Response to the Grounds of Opposition filed by Dr. Falk Pharma GmbH in opposition proceedings in EP2484822B1
1039	Prosecution history excerpts from U.S. Application No. 17/236,295, which issued as U.S. 11,266,598
1040-1070	RESERVED
1071	U.S. Publication No. US20110189299 to Okubo and Davies et al.
1072	2025-07-02 Deposition transcript of Dr. Martyn Davies

Exhibit No.	Description
1073	Schoepfer et al., "Variation in Endoscopic Activity Assessment and Endoscopy Score Validation in Adults With Eosinophilic Esophagitis," Clinical Gastroenterology and Hepatology, 17:1477-1488 (2019).
1074	2021-04-19 Assignment of U.S. Patent No. 8,771,729 from Adare Pharmaceuticals US, L.P. to Ellodi Pharmaceuticals, L.P. recorded at Reel 055966, Frame 0658.
1075	International Publication No. WO2003074029 to McEntee et al.
1076	International Publication No. WO2009078872 to Martin et al.
1077	U.S. Patent Publication No. 20030124184 to Mezaache et al.
1078	U.S. Patent Publication No. 20050019393 to Augsburger et al.
1079	U.S. Patent No. 7,384,921 to Tang et al.
1080	U.S. Patent Publication No. 20080132535 to Singh et al.
1081	U.S. Patent Publication No. 20090022799 to Barman
1082	Than, "Individualized Drugs for Individual Needs," Review of Optometry, 146:38-43 (2009)
1083	Iorgulescu, "Saliva between normal and pathological. Important factors in determining systemic and oral health," Journal of Medicine and Life 2:3003-307 (2009)
1084	2015-09-18 Assignment of U.S. Patent Application No. 10/827,106 (which published as Venkatesh, EX1020) to Adare Pharmaceuticals, Inc. recorded at Reel 036554, Frame 0829
1085	U.S. Patent No. 6,139,865 to Friend et al.
1086	2015-09-18 Assignment of U.S. Patent No. 6,139,865 to Adare Pharmaceuticals, Inc. recorded at Reel 036640, Frame 0591

Exhibit No.	Description
1087	Narmada et al., "Formulation, evaluation and optimization of fast dissolving tablets containing amlodipine besylate by sublimation method," ARS Pharmaceutica, 50:129-144 (2009)
1088	Khan et al., "Taste masking of ondansetron hydrochloride by polymer carrier system and formulation of rapid-disintegrating tablets," AAPS PharmSciTech 8:E1-E7 (2007)
1089	CLARITIN® (loratadine) FDA-approved package insert
1090	ZOFRAN® (ondansetron) FDA-approved package insert
1091	CLARINEX® (desloratadine) FDA-approved package insert
1092	PEPCID® (famotidine) FDA-approved package insert
1093	Declaration of Alan F. Parr, Pharm.D., Ph.D. supporting Petitioner Reply for U.S. 8,771,729
1094	August 14, 2025 Oral Hearing Transcript Regarding Patent Owner Request for Authorization to File a Motion to Strike in IPR2024-01197
1095	Petitioner Dr. Falk Pharma's Demonstrative Exhibits For Oral Hearing

Dated: October 22, 2025

Respectfully submitted,

By: */Nathanael R. Luman/*
Nathanael R. Luman (Reg. No. 63,160)
KNOBBE MARTENS OLSON & BEAR, LLP

Attorney for Petitioner Dr. Falk Pharma GmbH

CERTIFICATE OF SERVICE

The undersigned hereby certifies that on the date below a copy of this **PETITIONER'S UPDATED EXHIBIT LIST** was served by email on the Patent Owner at the following email addresses:

ssukduang@cooley.com; jcousin@cooley.com;

jdavies@cooley.com; iagarwal@cooley.com

Dated: October 22, 2025 By: */Nathanael R. Luman/*
Nathanael R. Luman (Reg. No. 63,160)
KNOBBE MARTENS OLSON & BEAR, LLP